[The effect of bencyclane hydrogen fumarate (Fludilate) on the adhesion of tumor cells in vivo and in vitro].
Bencyclane hydrogen fumarate (Fludilat) was tested on the stickiness of tumor cells in vivo and in vitro. It was intended to determine whether Fludilat reduced the cancer cell stickiness in vitro, and if the survival time of cancer cell carrying animals can be increased with Fludilat in vivo, or in combination with a cytostatic. For the in vitro trials, concentrations from 0.001 mg/ml to 1 mg/ml medium were chosen. The survival trial on NMRI-mice with Nemeth-Kellner lymphosarcoma was performed in three groups, each with 4-5 sub-groups: Control group--Fludilat 5 mg, 10 mg, 20 mg/kg bodyweight, Bleomycin--50 mg/kg bodyweight, 100 mg/kg bodyweight, 250 mg/kg bodyweight, Bleomycin 50 mg/kg bodyweight + Fludilat 5 mg/kg bodyweight, Bleomycin 100 mg/kg + Fludilat 10 mg/kg bodyweight, Bleomycin 250 mg/kg + Fludilat 20 mg/kg bodyweight. The sequence of deaths was determined, and the 50% survival time was taken as criterium for the effect of the treatment. The in vitro trials showed a complete removal of the monolayer of the tumor cells from the bottom of the culture flask, in doses of 0.01-1 mg/ml medium. In the in vivo trial an increase in the 50% survival time could be achieved in all groups. The results of combined therapy of Fludilat and Bleomycin were striking. In comparison to the control animals, the treated animals showed that the occurrence of solid abdominal metastases from the Nemeth-Kellner lymphosarcoma could be almost completely prevented, especially at high doses. The Ca++-antagonistic effect, in changing the surface of the cells, is discussed as a mechanism of action.
D000818:Animals; D001537:Bencyclane / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002448:Cell Adhesion / Q000187:drug effects; D003508:Cycloheptanes / Q000494:pharmacology*; D005650:Fumarates / Q000494:pharmacology; D006859:Hydrogen / Q000494:pharmacology; D066298:In Vitro Techniques; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology*
D003508:Cycloheptanes; D005650:Fumarates; D001761:Bleomycin; D001537:Bencyclane; D006859:Hydrogen
Der Einfluss von Bencyclan-hydrogenfumarat (Fludilat) auf die Haftfähigkeit von Tumorzellen in vivo und in vitro